Table 1.
Association between expression loss of homologous recombination markers and clinicopathological parameters in gastric cancer patients n (%)
| BRCA1 expression (n = 112) | ATM expression (n = 114) | ATR expression (n = 86) | MDC1 expression (n = 117) | Mre11 expression (n = 86) | ||||||
| BRCA1-negative/total cases | P value | ATM-negative/total cases | P value | ATR-negative/total cases | P value | MDC1-negative/total cases | P value | Mre11-negative/total cases | P value | |
| Age, yr (median) | ||||||||||
| < 61.3 | 15 (25.0) | 0.043 | 9 (16.1) | 0.133 | 8 (19.5) | 0.193 | 8 (14.3) | 0.625 | 2 (4.9) | 0.119 |
| ≥ 61.3 | 9 (17.3) | 14 (24.1) | 10 (22.2) | 5 (8.2) | 2 (4.4) | |||||
| Gender | ||||||||||
| Male | 15 (19.7) | 0.284 | 15 (19.5) | 0.715 | 12 (21.1) | 0.969 | 10 (12.7) | 0.430 | 3 (5.0) | 0.333 |
| Female | 9 (25.0) | 8 (21.6) | 6 (20.7) | 3 (7.9) | 1 (3.4) | |||||
| Lauren type | ||||||||||
| Intestinal | 4 (8.2) | 0.001 | 12 (24.0) | 0.846 | 8 (21.6) | 0.891 | 0 (0.0) | 0.001 | 2 (5.0) | 0.303 |
| Diffused | 20 (31.7) | 11 (17.2) | 10 (20.4) | 13 (19.7) | 2 (4.3) | |||||
| Tumor grade | ||||||||||
| I/II | 3 (10.7) | 0.047 | 7 (24.1) | 0.513 | 5 (29.4) | 0.327 | 0 (0.0) | 0.012 | 1 (4.2) | 0.742 |
| III | 15 (20.5) | 15 (20.5) | 10 (16.7) | 9 (12.0) | 3 (5.8) | |||||
| IV | 6 (54.5) | 1 (8.3) | 3 (33.3) | 4 (30.8) | 0 (0.0) | |||||
| Clinical stage | ||||||||||
| I/II | 4 (12.9) | 0.006 | 6 (19.4) | 0.560 | 6 (23.1) | 0.593 | 3 (9.4) | 0.092 | 2 (7.7) | 0.562 |
| III | 10 (16.9) | 11 (17.7) | 7 (16.7) | 5 (7.7) | 2 (4.2) | |||||
| IV | 10 (45.5) | 6 (28.6) | 5 (27.8) | 5 (25.0) | 0 (0.0) | |||||
BRCA1: Breast cancer type 1 susceptibility protein; ATM: Ataxia telangiectasia mutated; ATR: ATM-Rad3-related; MDC1: Mediator of DNA damage checkpoint protein 1; Mre11: Meiotic recombination 11.